|
|
    |
|
  |
|
TAMAS BARTFAI, PH.D., D. SC.
Professor, Department of Neuropharmacology & Director, Harold L. Dorris Neurological Research Center, Scripps Research Institute;
Dr. Tamas Bartfai became a member of the board in 2000. Dr. Bartfai has over 20 years of neuroscience research experience in both academia and pharmaceutical industry, and is currently professor in the Department of Neuropharmacology and a director of the Harold L. Dorris Neurological Research Center at Scripps Research Institute. Prior to his current academic posts, Dr. Bartfai was head of Central Nervous System Research and Development at F. Hoffmann-La Roche, Ltd. Earlier, Dr. Bartfai served as chairman of the Department of Neurochemistry and Neurotoxicology at Stockholm University, where he earned his Ph.D. in biochemistry.
FRANK BULENS, PH.D.
Investment Manager, Venture Capital-Life Sciences Department, GIMV Venture Capital
Dr. Frank Bulens has served as a member of the board since 1999. He is currently an investment manager for the venture capital-life sciences department of GIMV Venture Capital. Since 1985, Dr. Bulens has served as senior scientific advisor, post-doctoral researcher, scientific staff member and research assistant at the Center for Molecular and Vascular Biology at the Katholieke Universiteit Leuven in Belgium. Dr. Bulens received his Ph.D. and a master's degree in medical sciences from the Katholieke Universiteit Leuven and is currently an active board member for two other pharmaceutical companies.
ELIZABETH A. CZEREPAK
Managing Partner, Bear Stearns Health Innoventures
Ms. Czerepak became a member of the board in 2002. Ms. Czerepak has 18 years of pharmaceutical industry experience. Prior to Bear Stearns, she was Vice President for Business Development and a member of the Executive Board at BASF Pharma/Knoll Pharmaceutical Co., participating in the direction of all operational activities, including the launch of five products, and lead negotiator for several major global deals. Prior to BASF, she spent nine years at Hoffmann-La Roche in senior positions responsible for licensing, acquisitions, financial analysis and strategic planning. During that time she participated in over 25 transactions, including the $5.4 billion acquisition of Syntex. She managed strategic deal flow from Roche’s "window on technology" investments and Ms. Czerepak established RIMB Ventures to facilitate start-up companies to capitalize on innovation from the Roche Institute for Molecular Biology.
JEAN DELEAGE, PH.D.
Co-Founder, Alta Partners
Dr. Jean Deleage joined the Board of Directors in 1998. Dr. Deleage is one of the founders of Alta Partners, a venture capital firm investing in information technologies and life sciences companies. Prior to Alta Partners, Dr. Deleage was the founder of Sofinnova Paris, another venture capital investment firm, and later became president of Sofinnova, Inc. In addition, he has served on boards for a number of start-up companies. Dr. Deleage received a baccalaureate in France in 1958, a master's degree in electrical engineering from the Ecole Superieure d'Electricite in 1962 and a Ph.D. in economics from the Sorbonne in 1964. In 1993, he was awarded the Legion of Honor from the French government.
CYNTHIA LADD
President and Chief Executive Officer, AGY Therapeutics
Ms. Ladd joins AGY from Pharmacyclics Inc., where she served as Senior Vice President and General Counsel. At Pharmacyclics, Ms. Ladd was a member of the executive committee and, as Chief Legal Officer of the company, served as a business and legal advisor to senior management and the board of directors, as well as leading the legal, project management and regulatory affairs departments. Prior to that, Ms. Ladd spent more than a decade at Genentech Inc., serving as corporate legal counsel, most recently as Vice President of Corporate Law. At Genentech, Ms. Ladd played an active role in numerous product licenses and major strategic alliances as well as being involved in many organizational policy-setting initiatives, strategic planning and leadership committees. Prior to joining Genentech, Ms. Ladd was an associate at the law firms of Gray Cary Ware & Friedenrich and Wilson, Sonsini, Goodrich & Rosati, specializing in financing and collaborations for biotechnology and pharmaceutical companies. She holds a Masters of Science degree in animal nutrition/biochemistry from Cornell University and a law degree from Stanford University.
HANNS MÖHLER, PH.D.
Professor of Pharmacology and Director of the Institute of Pharmacology and Toxicology at the Swiss Federal Institute of Technology, Zurich and the University of Zurich; Advisor, HBM Partners
Dr. Hanns Möhler joined the Board of Directors, as well as our Scientific Advisory Board in 2003. Dr. Möhler is currently a professor of pharmacology and the director of the Institute of Pharmacology and Toxicology at the Swiss Federal Institute of Technology and the University of Zurich. Dr. Möhler studied chemistry and biochemistry at the Universities of Bonn, Tubingen and Freiburg, Germany. He is Director of the Swiss National Research Center in Neuroscience and is a member of the Swiss Academy of Medical Sciences.
KAROLY NIKOLICH, PH.D.
Founder & Chief Scientific Officer, AGY Therapeutics, Inc.
Dr. Karoly Nikolich founded AGY Therapeutics with Robert Swanson in 1998. Dr. Nikolich has over 20 years of biotechnology industry experience and is an expert in central nervous system disease therapeutics. Prior to founding AGY Therapeutics, Dr. Nikolich served as Vice President of Research at Lynx Therapeutics, Inc., a technology-based genomics company. Earlier, he worked in the research division of Genentech, Inc. for 12 years, where he initiated, established and directed Genentech's neuroscience research program. Dr. Nikolich graduated from Eotvos University in Budapest, Hungary, and completed a postdoctoral fellowship at Tulane University as well as a visiting scholarship at the University of California, San Francisco.
WILLIAM YOUNG, PH.D. - CHAIRMAN
Chairman & Chief Executive Officer, ViroLogic, Inc.
Dr. William Young became a member of the board in 2000. He is currently chairman of the board and chief executive officer of ViroLogic, Inc. Dr. Young came from Genentech, Inc., where he served as chief operating officer. Prior to joining Genentech, he worked at Eli Lilly and Company in various positions in production and process engineering, antibiotic process development and production management. He received a bachelor's degree in chemical engineering from Purdue University and a master's degree in business administration from Indiana University. In 1993, he was elected to the National Academy of Engineering division of the National Academy of Sciences for his contributions to the development of manufacturing technology for biotechnology-based drug products. In the year 2000, Dr. Young was awarded an Honorary Doctorate of Engineering by his alma mater, Purdue University.
|
|
